CTMX Stock Analysis: Buy, Sell, or Hold?
CTMX - CytomX Therapeutics, Inc.
$3.28
-0.01 (-0.30%)
âŧ
5d:
-2.38%
30d:
-1.5%
90d:
-12.77%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CTMX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CTMX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CTMX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CTMX is currently trading at $3.28, which is considered slightly low relative to its 30-day fair value range of $3.24 to $3.56.
Technical Outlook: Technically, CTMX is in a strong downtrend. The price is currently testing key support at $3.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CTMX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.25 (+273.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTMX is in a strong downtrend. The price is currently testing key support at $3.27. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CTMX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.25 (+273.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.24 -
$3.56
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 273.5% below Wall St target ($12.25)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.24 -
$3.56
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.27
Resistance Level
$3.60
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.93
Wall Street Target
$12.25
(+273.5%)
Revenue Growth (YoY)
-92.4%
Earnings Growth (YoY)
60.6%
Share & Embed Analysis
Last updated: August 23, 2026 6:30 PM ET
Data refreshes hourly during market hours. Next update: 7:30 PM
Data refreshes hourly during market hours. Next update: 7:30 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTMX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Ogden
SELL
19323 shares
2026-03-17
Marcia Belvin
SELL
31492 shares
2026-03-17
Sean A Mccarthy
SELL
118969 shares
2026-03-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 52 HOLD |
